Xue Jiang

Xue Jiang

Auto-generated profile, based on publicly available information

Xue Jiang

Department of Pathology, Duke University School of Medicine, Durham, North Carolina

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2022 in Carbohydrate Polymers
Verified
Journal Article
Closed access
TCTing Chen
Ting Chen
DZDanlu Zhang
Danlu Zhang
XTXiuzhi Tian
Xiuzhi Tian
Sheng QiangSheng Qiang
Sheng Qiang
CSCe Sun
Ce Sun
XJXue Jiang
Xue Jiang

13 August 2024 in Science Signaling
Verified
Journal Article
Closed access
CGClarice Gareri
Clarice Gareri
CPConrad T. Pfeiffer
Conrad T. Pfeiffer
XJXue Jiang
Xue Jiang
Joao A PauloJoao A Paulo
Joao A Paulo
SGSteven P. Gygi
Steven P. Gygi
HRHoward A. Rockman
Howard A. Rockman
Different ligands stabilize specific conformations of the angiotensin II type 1 receptor (AT1R) that direct distinct signaling cascades mediated by heterotrimeric G proteins or β-arrestin. These different active conformations are thought to engage distinct intracellular transducers because of differential phosphorylation patterns in the receptor C-terminal tail (the “barcode” hypothesis). Here, we identified the AT1R barcodes for the endogenous agonist AngII, which stimulates both G protein activation and β-arrestin recruitment, and for a synthetic biased agonist that only stimulates β-arrestin recruitment. The endogenous and β-arrestin–biased agonists induced two different ensembles of phosphorylation sites along the C-terminal tail. The phosphorylation of eight serine and threonine residues in the proximal and middle portions of the tail was required for full β-arrestin functionality, whereas phosphorylation of the serine and threonine residues in the distal portion of the tail had little influence on β-arrestin function. Similarly, molecular dynamics simulations showed that the proximal and middle clusters of phosphorylated residues were critical for stable β-arrestin–receptor interactions. These findings demonstrate that ligands that stabilize different receptor conformations induce different phosphorylation clusters in the C-terminal tail as barcodes to evoke distinct receptor-transducer engagement, receptor trafficking, and signaling.

29 March 2024 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
LFLin Fu
Lin Fu
JZJingjing Zhang
Jingjing Zhang
YWYanli Wang
Yanli Wang
HWHuiyin Wu
Huiyin Wu
XXXiumei Xu
Xiumei Xu
BLBin Liang
Bin Liang
Lipid droplets (LDs) are composed of a core of neutral lipids wrapped by a phospholipid (PL) monolayer containing several hundred proteins that vary between different cells or organisms. How LD proteins target to LDs is still largely unknown. Here, we show that RNAi knockdown or gene mutation of let-767, encoding a member of hydroxysteroid dehydrogenase (HSD), displaced the LD localization of three well-known LD proteins: DHS-3 (dehydrogenase/reductase), PLIN-1 (perilipin), and DGAT-2 (diacylglycerol O-acyltransferase 2), and also prevented LD growth in Caenorhabditis elegans. LET-767 interacts with ARF-1 (ADP-ribosylation factor 1) to prevent ARF-1 LD translocation for appropriate LD protein targeting and lipid homeostasis. Deficiency of LET-767 leads to the release of ARF-1, which further recruits and promotes translocation of ATGL-1 (adipose triglyceride lipase) to LDs for lipolysis. The displacement of LD proteins caused by LET-767 deficiency could be reversed by inhibition of either ARF-1 or ATGL-1. Our work uncovers a unique LET-767 for determining LD protein targeting and maintaining lipid homeostasis.

11 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
JYJianpeng Yu
Jianpeng Yu
CJChen Jin
Chen Jin
CSCheng Su
Cheng Su
DMDavid Moon
David Moon
MSMichael A Sun
Michael A Sun
JHJiaoti Huang
Jiaoti Huang
Purpose: Purine metabolism is a promising therapeutic target in cancer; however, how cancer cells respond to purine shortage, particularly their adaptation and vulnerabilities, remains unclear. Experimental Design: Using the recently developed purine shortage–inducing prodrug DRP-104 and genetic approaches, we investigated the responses in prostate, lung, and glioma cancer models. Results: We demonstrate that when de novo purine biosynthesis is compromised, cancer cells employ microtubules to assemble purinosomes, multiprotein complexes of de novo purine biosynthesis enzymes that enhance purine biosynthesis efficiency. Although this process enables tumor cells to adapt to purine shortage stress, it also renders them more susceptible to the microtubule-stabilizing chemotherapeutic drug docetaxel. Furthermore, we show that although cancer cells primarily rely on de novo purine biosynthesis, they also exploit methylthioadenosine phosphorylase (MTAP)–mediated purine salvage as a crucial alternative source of purine supply, especially under purine shortage stress. In support of this finding, combining DRP-104 with an MTAP inhibitor significantly enhances tumor suppression in prostate cancer models in vivo. Finally, despite the resilience of the purine supply machinery, purine shortage–stressed tumor cells exhibit increased DNA damage and activation of the cGAS–STING pathway, which may contribute to impaired immunoevasion and provide a molecular basis of the previously observed DRP-104–induced antitumor immunity. Conclusions: Together, these findings reveal purinosome assembly and purine salvage as key mechanisms of cancer cell adaptation and resilience to purine shortage while identifying microtubules, MTAP, and immunoevasion deficits as therapeutic vulnerabilities.

15 October 2025
Verified
Other
Open access
JYJianpeng Yu
Jianpeng Yu
CJChen Jin
Chen Jin
CSCheng Su
Cheng Su
DMDavid Moon
David Moon
MSMichael A Sun
Michael A Sun
JHJiaoti Huang
Jiaoti Huang
Prostate cancer cells develop adaptation to purine shortage inducer, such as DRP-104, and employ microtubules to assemble purinosome to enhance purine biosynthesis efficiency.

15 October 2025
Verified
Other
Open access
JYJianpeng Yu
Jianpeng Yu
CJChen Jin
Chen Jin
CSCheng Su
Cheng Su
DMDavid Moon
David Moon
MSMichael A Sun
Michael A Sun
JHJiaoti Huang
Jiaoti Huang
Purpose:Purine metabolism is a promising therapeutic target in cancer; however, how cancer cells respond to purine shortage, particularly their adaptation and vulnerabilities, remains unclear.Experimental Design:Using the recently developed purine shortage–inducing prodrug DRP-104 and genetic approaches, we investigated the responses in prostate, lung, and glioma cancer models.Results:We demonstrate that when de novo purine biosynthesis is compromised, cancer cells employ microtubules to assemble purinosomes, multiprotein complexes of de novo purine biosynthesis enzymes that enhance purine biosynthesis efficiency. Although this process enables tumor cells to adapt to purine shortage stress, it also renders them more susceptible to the microtubule-stabilizing chemotherapeutic drug docetaxel. Furthermore, we show that although cancer cells primarily rely on de novo purine biosynthesis, they also exploit methylthioadenosine phosphorylase (MTAP)–mediated purine salvage as a crucial alternative source of purine supply, especially under purine shortage stress. In support of this finding, combining DRP-104 with an MTAP inhibitor significantly enhances tumor suppression in prostate cancer models in vivo. Finally, despite the resilience of the purine supply machinery, purine shortage–stressed tumor cells exhibit increased DNA damage and activation of the cGAS–STING pathway, which may contribute to impaired immunoevasion and provide a molecular basis of the previously observed DRP-104–induced antitumor immunity.Conclusions:Together, these findings reveal purinosome assembly and purine salvage as key mechanisms of cancer cell adaptation and resilience to purine shortage while identifying microtubules, MTAP, and immunoevasion deficits as therapeutic vulnerabilities.